Coherus Oncology, Inc.
Clinical trials sponsored by Coherus Oncology, Inc., explained in plain language.
-
New combo therapy aims to shrink advanced tumors
Disease control Recruiting nowThis early-stage study tests a new drug (CHS-114) combined with an immunotherapy (toripalimab) in people with advanced or metastatic solid tumors that have not responded to prior treatments. The main goal is to check safety and see if the combination can shrink tumors. About 154 …
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 05:32 UTC
-
New antibody drug enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called CHS-114 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein on certain immune cells to help the body fight cancer. About 87 participants will receive the drug alone or …
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New hope for advanced nose cancer: immunotherapy plus chemo tested
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can shrink tumors or slow cancer growth in people with nasopharyngeal cancer that has come back or spread. About 100 adults who have not had prior treatment for…
Phase: PHASE4 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC